Abstract
Purpose: :
Patients with diabetic macular edema associated with peripheral nonperfusion may represent a distinct category of DME that is characterized by ischemia-driven VEGF production. A novel treatment strategy targeting the underlying pathobiology may provide effective and durable effects.
Methods: :
Prospective, randomized trial comparing a novel approach of angiography-directed peripheral scatter laser + ranibizumab to standard therapy with macular laser + triamcinolone. Primary outcome is visual acuity; secondary outcomes are central foveal thickness on OCT and need for retreatment at 6 months.
Results: :
See Table 1
Conclusions: :
Patients with DME associated with peripheral nonperfusion appear to be a distinct population. A novel treatment strategy addressing the underlying pathobiology may provide an effective and durable treatment benefit.
Clinical Trial: :
www.clinicaltrials.gov Pro00002813
Keywords: diabetic retinopathy • vascular endothelial growth factor • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials